KLRA vs OMDA
KLRA: A clinical-stage biotech developing a diversified pipeline of GLP-1-based obesity management drugs, led by a dual GLP-1/GIP agonist injectable designed to deliver superior weight loss potential. OMDA: Virtual care platform combining human health coaches and AI-driven technology to deliver preventive and chronic disease management programs for cardiometabolic conditions, obesity, and musculoskeletal health at scale.
Side-by-side fundamentals
| Metric | KLRA | OMDA | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $17.48 | $20.58 | |
| Market cap as of 2026-08-01 | $2.3B | $1.2B | |
| Net margin as of 2026-08-01 | n/a | -2.2% | |
| Gross margin as of 2026-08-01 | n/a | +66.3% | |
| Operating margin as of 2026-08-01 | n/a | -3.7% | |
| ROE as of 2026-08-01 | -23.4% | -2.8% | OMDA higher |
| ROA as of 2026-08-01 | -21.5% | -2.1% | OMDA higher |
| Debt / equity as of 2026-08-01 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-08-01 | n/a | +42.0% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +45.6% | |
| Beta as of 2026-08-01 | 1.71 | 1.36 | |
| 1-year return as of 2026-07-27 close | n/a | +7.1% |
Fundamentals: market data, as of 2026-08-01. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.